Supernus Q3 2026 net earnings swing to $20.91 million from year-earlier loss
SUPN•Supernus Pharmaceuticals reported third-quarter 2026 net earnings of $20.9 million, compared with a year-earlier loss, as revenue rose 18% to $226.8 million. It raised stand-alone 2026 revenue guidance to $875 million–$900 million and expects its merger with Indivior to close November 2, 2026, with $125 million in annual cost synergies targeted.
1. Earnings and outlook
Supernus Pharmaceuticals swung to third-quarter 2026 net earnings of $20.9 million from a year-earlier loss, while total revenue increased 18% year over year to $226.8 million. The company raised its stand-alone full-year 2026 revenue guidance to $875 million–$900 million; the outlook will no longer apply once its merger with Indivior closes, which is expected November 2, 2026. The merger targets $125 million in annual cost synergies.
